These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35106949)

  • 1. Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humans.
    Nussbaum JC; Hussain A; Ma B; Min KC; Chen Q; Tomek C; Iwamoto M; Stoch SA
    Pharmacol Res Perspect; 2022 Feb; 10(1):e00924. PubMed ID: 35106949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single- and Multiple-Dose Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist, in Healthy Adults.
    Nussbaum JC; Hussain A; Butera P; Ford AP; Kitt MM; O'Neill EA; Smith S; Vargas G; O'Reilly T; Wynne C; Stoch SA; Iwamoto M
    J Clin Pharmacol; 2024 Aug; 64(8):1023-1029. PubMed ID: 38651193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial.
    Smith JA; Kitt MM; Morice AH; Birring SS; McGarvey LP; Sher MR; Li YP; Wu WC; Xu ZJ; Muccino DR; Ford AP;
    Lancet Respir Med; 2020 Aug; 8(8):775-785. PubMed ID: 32109425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor Antagonist.
    Nussbaum JC; Hussain A; Min KC; Marbury TC; Lasseter K; Stoch SA; Iwamoto M
    J Clin Pharmacol; 2022 Nov; 62(11):1435-1444. PubMed ID: 35656754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Pharmacokinetic Interaction Between Gefapixant (MK-7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin.
    McCrea JB; Hussain A; Ma B; Garrett GC; Evers R; Laabs JE; Stoch SA; Iwamoto M
    Clin Pharmacol Drug Dev; 2022 Mar; 11(3):406-412. PubMed ID: 34821075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the Effect of Pyrimethamine, a Potent Inhibitor of Multidrug and Toxin Extrusion Protein 1/2K, on the Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor Antagonist.
    Nussbaum JC; Hussain A; Ma B; Min KC; Evers R; Li Y; Garrett G; Stoch SA; Iwamoto M
    Clin Pharmacol Drug Dev; 2022 Jan; 11(1):123-128. PubMed ID: 34145987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough.
    Muccino D; Green S
    Pulm Pharmacol Ther; 2019 Jun; 56():75-78. PubMed ID: 30880151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mass Balance and Metabolic Pathways of Eliapixant, a P2X3 Receptor Antagonist, in Healthy Male Volunteers.
    Reif S; Schultze-Mosgau MH; Engelen A; Piel I; Denner K; Roffel A; Tiessen R; Klein S; Francke K; Rottmann A
    Eur J Drug Metab Pharmacokinet; 2024 Jan; 49(1):71-85. PubMed ID: 38044419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study.
    Morice AH; Kitt MM; Ford AP; Tershakovec AM; Wu WC; Brindle K; Thompson R; Thackray-Nocera S; Wright C
    Eur Respir J; 2019 Jul; 54(1):. PubMed ID: 31023843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The discovery and development of gefapixant.
    Ford AP; Dillon MP; Kitt MM; Gever JR
    Auton Neurosci; 2021 Nov; 235():102859. PubMed ID: 34403981
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration.
    Garceau D; Chauret N
    Pulm Pharmacol Ther; 2019 Jun; 56():56-62. PubMed ID: 30902655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gefapixant: First Approval.
    Markham A
    Drugs; 2022 Apr; 82(6):691-695. PubMed ID: 35347635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study.
    Friedrich C; Francke K; Gashaw I; Scheerans C; Klein S; Fels L; Smith JA; Hummel T; Morice A
    Clin Pharmacokinet; 2022 Aug; 61(8):1143-1156. PubMed ID: 35624408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Excretion balance and pharmacokinetics following a single oral dose of [
    Ogasawara K; Xu C; Kanamaluru V; Siebers N; Surapaneni S; Ridoux L; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):307-314. PubMed ID: 32748109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications.
    Marucci G; Dal Ben D; Buccioni M; Martí Navia A; Spinaci A; Volpini R; Lambertucci C
    Expert Opin Ther Pat; 2019 Dec; 29(12):943-963. PubMed ID: 31726893
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending-dose study in healthy young men.
    Friedrich C; Singh D; Francke K; Klein S; Hetzel T; Zolk O; Gashaw I; Scheerans C; Morice A
    Br J Clin Pharmacol; 2024 Aug; 90(8):2004-2018. PubMed ID: 38775025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Pharmacokinetics of 3 Weeks of Orally Administered Gefapixant in Healthy Younger and Older Adults.
    Nussbaum J; Hussain A; Ford A; Butera P; Kitt M; Smith S; Stoch A; Iwamoto M
    Lung; 2022 Jun; 200(3):315-323. PubMed ID: 35670873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans.
    Bhattacharya C; Sandinge AS; Bragg RA; Heijer M; Yan J; Andersson LC; Jurva U; Pelay-Gimeno M; Vaes WHJ; de Ligt RAF; Gränfors M; Amilon C; Lindstedt EL; Menakuru SR; Garkaviy P; Weidolf L; Gopaul VS
    Drug Metab Dispos; 2023 Apr; 51(4):451-463. PubMed ID: 36639243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. P2X3-Receptor Antagonists as Potential Antitussives: Summary of Current Clinical Trials in Chronic Cough.
    Dicpinigaitis PV; McGarvey LP; Canning BJ
    Lung; 2020 Aug; 198(4):609-616. PubMed ID: 32661659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absorption, Metabolism and Excretion of Surufatinib in Rats and Humans.
    Li K; Ma S; Miao L; Fan S; Pan B; Zhang W; Su W; Xiong Y; Gu Z; Guo L; Sai Y
    Curr Drug Metab; 2020; 21(5):357-367. PubMed ID: 32407271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.